Instituto Académico Pedagógico de Ciencias Básicas y Aplicadas, Universidad Nacional de Villa María, Villa María, Córdoba, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
J Biomol Struct Dyn. 2022 Aug;40(12):5653-5664. doi: 10.1080/07391102.2021.1872420. Epub 2021 Jan 18.
2020 will be remembered worldwide for the outbreak of Coronavirus disease (COVID-19), which quickly spread until it was declared as a global pandemic. The main protease (Mpro) of SARS-CoV-2, a key enzyme in coronavirus, represents an attractive pharmacological target for inhibition of SARS-CoV-2 replication. Here, we evaluated whether the anti-inflammatory drug Ibuprofen, may act as a potential SARS-CoV-2 Mpro inhibitor, using an study. From molecular dynamics (MD) simulations, we also evaluated the influence of ionic strength on the affinity and stability of the Ibuprofen-Mpro complexes. The docking analysis shows that R(-)Ibuprofen and S(+)Ibuprofen isomers can interact with multiple key residues of the main protease, through hydrophobic interactions and hydrogen bonds, with favourable binding energies (-6.2 and -5.7 kcal/mol, respectively). MM-GBSA and MM-PBSA calculations confirm the affinity of these complexes, in terms of binding energies. It also demonstrates that the ionic strength modifies significantly their binding affinities. Different structural parameters calculated from the MD simulations (120 ns) reveal that these complexes are conformational stable in the different conditions analysed. In this context, the results suggest that the condition 2 (0.25 NaCl) bind more tightly the Ibuprofen to Mpro than the others conditions. From the frustration analysis, we could characterize two important regions (Cys44-Pro52 and Linker loop) of this protein involved in the interaction with Ibuprofen. In conclusion, our findings allow us to propose that racemic mixtures of the Ibuprofen enantiomers might be a potential treatment option against SARS-CoV-2 Mpro. However, further research is necessary to determinate their possible medicinal use.Communicated by Ramaswamy H. Sarma.
2020 年将因冠状病毒病 (COVID-19) 的爆发而在全球范围内被铭记,这种疾病迅速传播,直到被宣布为全球大流行。SARS-CoV-2 的主要蛋白酶 (Mpro) 是冠状病毒中的一种关键酶,代表了抑制 SARS-CoV-2 复制的有吸引力的药物靶标。在这里,我们使用 研究评估了抗炎药布洛芬是否可能作为 SARS-CoV-2 Mpro 的潜在抑制剂。从分子动力学 (MD) 模拟中,我们还评估了离子强度对布洛芬-Mpro 复合物亲和力和稳定性的影响。对接分析表明,R(-)布洛芬和 S(+)布洛芬对映异构体可以通过疏水相互作用和氢键与主蛋白酶的多个关键残基相互作用,具有有利的结合能 (-6.2 和 -5.7 kcal/mol,分别)。MM-GBSA 和 MM-PBSA 计算证实了这些复合物的亲和力,就结合能而言。它还表明,离子强度会显著改变它们的结合亲和力。从 MD 模拟计算的不同结构参数(120 ns)表明,这些复合物在不同分析条件下构象稳定。在这种情况下,结果表明条件 2 (0.25 NaCl) 使 Ibuprofen 与 Mpro 的结合比其他条件更紧密。从挫折分析中,我们可以表征该蛋白中与 Ibuprofen 相互作用的两个重要区域 (Cys44-Pro52 和 Linker 环)。总之,我们的研究结果表明,布洛芬对映异构体的外消旋混合物可能是治疗 SARS-CoV-2 Mpro 的潜在选择。然而,需要进一步的研究来确定它们可能的药用用途。由 Ramaswamy H. Sarma 传达。